Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant

Chemistry and Biology

Volumn 17, Issue 1, 2010, Pages 46-56

  Basse, Nicolas ^a   Kaar, Joel L ^a   Settanni, Giovanni ^a   Joerger, Andreas C ^a   Rutherford, Trevor J ^a   Fersht, Alan R ^a  

^a MRC CENTRE FOR PROTEIN ENGINEERING   (United Kingdom)

Author keywords

CELLCYCLE; CHEMBIO; HUMDISEASE

Indexed keywords

2 PROPANOL; ANTINEOPLASTIC AGENT; LIGAND; PROTEIN P53;

ARTICLE; BINDING SITE; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOLECULAR DYNAMICS; MUTATION; NEOPLASM; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; X RAY CRYSTALLOGRAPHY;

2-PROPANOL; ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; MUTATION; NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; TUMOR SUPPRESSOR PROTEIN P53;

RUMEX;

EID: 75149134332     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2009.12.011     Document Type: Article

References (58)

1. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., Moriarty N.W., Read R.J., Sacchettini J.C., Sauter N.K., and Terwilliger T.C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58 (2002) 1948-1954
2. Bahar I., Atilgan A.R., and Erman B. Direct evaluation of thermal fluctuations in proteins using a single-parameter harmonic potential. Fold. Des. 2 (1997) 173-181
3. Bahar I., Wallqvist A., Covell D.G., and Jernigan R.L. Correlation between native-state hydrogen exchange and cooperative residue fluctuations from a simple model. Biochemistry 37 (1998) 1067-1075
4. Bahar I., Erman B., Jernigan R.L., Atilgan A.R., and Covell D.G. Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function. J. Mol. Biol. 285 (1999) 1023-1037
5. Bembenek S.D., Tounge B.A., and Reynolds C.H. Ligand efficiency and fragment-based drug discovery. Drug Discov. Today 14 (2009) 278-283
6. Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., and Fersht A.R. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. USA 105 (2008) 10360-10365
7. Bohm H.J., Banner D., Bendels S., Kansy M., Kuhn B., Muller K., Obst-Sander U., and Stahl M. Fluorine in medicinal chemistry. ChemBioChem 5 (2004) 637-643
8. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., and Karplus M. Charmm-a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4 (1983) 187-217
9. Bullock A.N., and Fersht A.R. Rescuing the function of mutant p53. Nat. Rev. Cancer 1 (2001) 68-76
10. Bullock A.N., Henckel J., DeDecker B.S., Johnson C.M., Nikolova P.V., Proctor M.R., Lane D.P., and Fersht A.R. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA 94 (1997) 14338-14342
11. Bullock A.N., Henckel J., and Fersht A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19 (2000) 1245-1256
12. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., and Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8 (2002) 282-288
13. Bykov V.J., Issaeva N., Zache N., Shilov A., Hultcrantz M., Bergman J., Selivanova G., and Wiman K.G. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 280 (2005) 30384-30391
14. Ciulli A., and Abell C. Fragment-based approaches to enzyme inhibition. Curr. Opin. Biotechnol. 18 (2007) 489-496
15. Congreve M., Carr R., Murray C., and Jhoti H. A rule of three for fragment-based lead discovery?. Drug Discov. Today 8 (2003) 876-877
16. Das K., Bauman J.D., Clark Jr. A.D., Frenkel Y.V., Lewi P.J., Shatkin A.J., Hughes S.H., and Arnold E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. USA 105 (2008) 1466-1471
17. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall III W.B., Snoeyink J., Richardson J.S., and Richardson D.C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35 (2007) W375-383
18. Dennis S., Kortvelyesi T., and Vajda S. Computational mapping identifies the binding sites of organic solvents on proteins. Proc. Natl. Acad. Sci. USA 99 (2002) 4290-4295
19. Di Como C.J., and Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16 (1998) 2527-2539
20. Erlanson D.A. Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol. 17 (2006) 643-652
21. Evans P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62 (2006) 72-82
22. Foster B.A., Coffey H.A., Morin M.J., and Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 286 (1999) 2507-2510
23. Friedler A., Hansson L.O., Veprintsev D.B., Freund S.M., Rippin T.M., Nikolova P.V., Proctor M.R., Rudiger S., and Fersht A.R. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. USA 99 (2002) 937-942
24. Friedler A., Veprintsev D.B., Hansson L.O., and Fersht A.R. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J. Biol. Chem. 278 (2003) 24108-24112
25. Guvench O., and MacKerell Jr. A.D. Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput. Biol. 5 (2009) e1000435
26. Hajduk P.J., and Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6 (2007) 211-219
27. Hajduk P.J., Dinges J., Miknis G.F., Merlock M., Middleton T., Kempf D.J., Egan D.A., Walter K.A., Robins T.S., Shuker S.B., et al. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J. Med. Chem. 40 (1997) 3144-3150
28. Hajduk P.J., Huth J.R., and Fesik S.W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48 (2005) 2518-2525
29. Hajduk P.J., Huth J.R., and Tse C. Predicting protein druggability. Drug Discov. Today 10 (2005) 1675-1682
30. Hann B.C., and Lane D.P. The dominating effect of mutant p53. Nat. Genet. 9 (1995) 221-222
31. Hess B., Kutzner C., van der Spoel D., and Lindahl E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4 (2008) 435-447
32. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
33. Horovitz A., and Fersht A.R. Co-operative interactions during protein folding. J. Mol. Biol. 224 (1992) 733-740
34. Humphrey W., Dalke A., and Schulten K. VMD: Visual molecular dynamics. J. Mol. Graph. 14 (1996) 33-38
35. Interlandi G., Wetzel S.K., Settanni G., Pluckthun A., and Caflisch A. Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments. J. Mol. Biol. 375 (2008) 837-854
36. Issaeva N., Friedler A., Bozko P., Wiman K.G., Fersht A.R., and Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. USA 100 (2003) 13303-13307
37. Joerger A.C., and Fersht A.R. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26 (2007) 2226-2242
38. Joerger A.C., and Fersht A.R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77 (2008) 557-582
39. Joerger A.C., Allen M.D., and Fersht A.R. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J. Biol. Chem. 279 (2004) 1291-1296
40. Joerger A.C., Ang H.C., and Fersht A.R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl. Acad. Sci. USA 103 (2006) 15056-15061
41. Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L., Haran T.E., and Shakked Z. Structural basis of DNA recognition by p53 tetramers. Mol. Cell 22 (2006) 741-753
42. Lambert J.M., Gorzov P., Veprintsev D.B., Soderqvist M., Segerback D., Bergman J., Fersht A.R., Hainaut P., Wiman K.G., and Bykov V.J. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15 (2009) 376-388
43. Leslie A.G. Integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 55 (1999) 1696-1702
44. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 (1991) 453-456
45. Liepinsh E., and Otting G. Organic solvents identify specific ligand binding sites on protein surfaces. Nat. Biotechnol. 15 (1997) 264-268
46. MacKerell A.D., Bashford D., Bellott M., Dunbrack R.L., Evanseck J.D., Field M.J., Fischer S., Gao J., Guo H., Ha S., et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102 (1998) 3586-3616
47. Meyer B., and Peters T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Ed. Engl. 42 (2003) 864-890
48. Nikolova P.V., Henckel J., Lane D.P., and Fersht A.R. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc. Natl. Acad. Sci. USA 95 (1998) 14675-14680
49. North S., Pluquet O., Maurici D., El-Ghissassi F., and Hainaut P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol. Carcinog. 33 (2002) 181-188
50. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., and Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28 (2007) 622-629
51. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., Chipot C., Skeel R.D., Kale L., and Schulten K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26 (2005) 1781-1802
52. Seco J., Luque F.J., and Barril X. Binding site detection and druggability index from first principles. J. Med. Chem. 52 (2009) 2363-2371
53. Seeber M., Cecchini M., Rao F., Settanni G., and Caflisch A. Wordom: a program for efficient analysis of molecular dynamics simulations. Bioinformatics 23 (2007) 2625-2627
54. Teague S.J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 2 (2003) 527-541
55. Tobi D., and Bahar I. Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Proc. Natl. Acad. Sci. USA 102 (2005) 18908-18913
56. Turk, D. (1992). PhD thesis. Technische Universität München, Munich, Germany.
57. Vousden K.H., and Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8 (2007) 275-283
58. Yang L.W., Rader A.J., Liu X., Jursa C.J., Chen S.C., Karimi H.A., and Bahar I. oGNM: online computation of structural dynamics using the Gaussian Network Model. Nucleic Acids Res. 34 (2006) W24-31